Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

12 Dec 2018 16:35

RNS Number : 3061K
GlaxoSmithKline PLC
12 December 2018
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharma Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

9 (partnership shares)

£14.9439

9 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

18 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQLLFFVLFXFBZ
Date   Source Headline
25th Apr 201812:00 pmRNS1st Quarter Results
24th Apr 20185:41 pmRNSTrelegy Ellipta expanded US COPD indication
20th Apr 20183:15 pmRNSDirector/PDMR Shareholding
20th Apr 20183:15 pmRNSDirector/PDMR Shareholding
19th Apr 20187:00 amRNSIMPACT study shows benefits of Trelegy Ellipta
18th Apr 201810:34 amRNSLandmark IMPACT study to be published in NEJM
18th Apr 201810:02 amRNSIMPACT study shows benefits of Trelegy Ellipta
17th Apr 20181:47 pmRNSDirector/PDMR Shareholding
17th Apr 20181:36 pmRNSDirector/PDMR Shareholding
17th Apr 20181:30 pmRNSDirector/PDMR Shareholding
17th Apr 20181:24 pmRNSDirector/PDMR Shareholding
17th Apr 20181:20 pmRNSDirector/PDMR Shareholding
13th Apr 20183:50 pmRNSDirector/PDMR Shareholding
13th Apr 20183:44 pmRNSDirector/PDMR Shareholding
13th Apr 201811:32 amRNSNotice of GM
12th Apr 20183:04 pmRNSDirector/PDMR Shareholding
3rd Apr 20184:14 pmRNSTotal Voting Rights
29th Mar 20181:00 pmRNSNotice of AGM
27th Mar 20187:00 amRNSGSK agrees to acquire CH business from Novartis
23rd Mar 201811:21 amRNSViiV - CHMP positive opinion for Juluca in Europe
23rd Mar 20187:44 amRNSUpdate regarding Pfizer Inc. Consumer Healthcare
23rd Mar 20187:00 amRNSShingrix approved in Europe and Japan
19th Mar 20187:00 amRNSGSK 2017 Form 20-F
13th Mar 20182:10 pmRNSAnnual Financial Report
12th Mar 20184:30 pmRNSDirector/PDMR Shareholding
8th Mar 20188:00 amRNSGSK announces labelling update to Relvar Ellipta
5th Mar 20185:01 pmRNSViiV Healthcare announces new dolutegravir data
5th Mar 20182:47 pmRNSNucala OSMO study presented at AAAAI-WAO congress
5th Mar 201812:04 pmRNSDirector/PDMR Shareholding
2nd Mar 20181:11 pmRNSDirector/PDMR Shareholding
1st Mar 201811:16 amRNSTotal Voting Rights
22nd Feb 20184:54 pmRNSDirector/PDMR Shareholding
20th Feb 20181:17 pmRNSDirector/PDMR Shareholding
20th Feb 20181:16 pmRNSDirector/PDMR Shareholding
20th Feb 20181:15 pmRNSDirector/PDMR Shareholding
19th Feb 20186:12 pmRNSDirector/PDMR Shareholding
16th Feb 20185:29 pmRNSDirector/PDMR Shareholding
16th Feb 20185:25 pmRNSDirector/PDMR Shareholding
16th Feb 201811:20 amRNSDirector/PDMR Shareholding
15th Feb 20186:09 pmRNSDirector/PDMR Shareholding
15th Feb 20185:57 pmRNSDirector/PDMR Shareholding
15th Feb 20185:53 pmRNSDirector/PDMR Shareholding
14th Feb 20189:00 amRNSGSK submits landmark IMPACT data - Trelegy Ellipta
13th Feb 20184:44 pmRNSDirector/PDMR Shareholding
12th Feb 20182:43 pmRNSDirector/PDMR Shareholding
12th Feb 201812:47 pmRNSDirector/PDMR Shareholding
8th Feb 20189:31 amRNSViiV Healthcare launches new two-drug HIV study
8th Feb 20187:00 amRNSViiV files patent infringement litigation
7th Feb 20181:19 pmRNSDirector/PDMR Shareholding
7th Feb 201812:01 pmRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.